Arrowhead describes new RNAi delivery vehicle; FDA delays oral disintegrating tablet for ADHD;

> RNAi specialist Arrowhead discussed new enhancements to the company's RNAi drug delivery platform, including a new proprietary subcutaneous delivery vehicle, at the meeting of the Oligonucleotide Therapeutics Society in the Netherlands. More

> The FDA had identified deficiencies with Neos Therapeutics' extended-release oral disintegrating tablet for ADHD during a review of the candidate's New Drug Application. More

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.